Request an Appointment

Cancer Answer Line:

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

07-267 Collection of Blood and Tissue from Patients with Upper Aerodigestive Malignancies for Research Purposes (The UAM Tissue Resource)Main Campus  Esophageal, Head & Neck, Lung, Mesothelioma, Thyroid
ASTX 151212-974A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)Main Campus  Lung
CHRV 0090 Clinical predictors of benefit from pemetrexed in patients with metastatic non small cell lung cancerMain Campus  Lung
CHRV 0120 Clinical Implications of Routine Testing for Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Nonsquamous Non-small Cell Lung Cancer.Main Campus  Lung
CLVS 151414-775TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) with the T790M Resistance MutationFlorida Weston, Main Campus Phase 2NSCLC (Non-small cell lung cancer)
ECOG 550812-108Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLCBeachwood, Fairview, Hillcrest, Independence, Main Campus, North Coast Cancer, Parma, Strongsville, Wooster Phase 3Lung
ECOG 5508FLA11-022Randomized Phase III study of maintenance therapy with bevacizumab, pemetrexed, or a combination of bevacizumab and pemetrexed following carboplatin, paclitaxel and bevacizumab for advanced non-squamous NSCLCFlorida WestonStage 4Phase 3NSCLC (Non-small cell lung cancer)
ESAI 151414-697A Multicenter, Open-Label Phase 2 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the LungFlorida Weston, Main Campus Phase 2Lung
MRK 151314-287A Phase I/II Study of MK-3475 (SCH900475) in Combination with Chemotherapy or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung CarcinomaMain CampusStage 3B, Stage 4Phase 1, Phase 2Lung, NSCLC (Non-small cell lung cancer)
NLG 151313-637An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Hyper-Acute Lung (tergenpumatucel-L) immunotherapy versus docetaxel in progressive or relapsed non-small cell lung cancerMain Campus Phase 2, Phase 3Lung
RPCI 1509CC760A Phase II Randomized Study of 2 Stereotactic Body Radiation Therapy (SBRT) Regimens for Medically Inoperable Patients with Node Negative, Peripheral Non - Small Cell Lung CancerMain Campus Phase 2Lung
RTOG 0538CC707Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and EtoposideFairview, Hillcrest, Independence, Main Campus, North Coast Cancer, Strongsville, Wooster Phase 3Lung
RTOG 0839CC00137Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed By Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung CancerMain Campus, StrongsvilleStage 3APhase 2Lung
RTOG 1106081201CRandomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)Main Campus  Lung
RTOG 130614-577A Randomized Phase II Study Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung CancerBeachwood, Fairview, Hillcrest, Independence, Main Campus, North Coast Cancer, Strongsville, Wooster Phase 2Lung, NSCLC (Non-small cell lung cancer)
SWOG 140014-894Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung CancerMain Campus Phase 2, Phase 3Lung
UNC 151212-1096LCCC 1123: Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR-TKIMain CampusStage 4Phase 2Lung
UNC 251213-028A Phase II, multicenter, single arm study of the tolerability of weekly nab-paclitaxel as second line treatment for elderly patients with advanced lung cancerMain Campus Phase 2Lung

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).


Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.